Progenetics will market and distribute Biocept's complete portfolio of Target Selector liquid biopsy assays in Israel. Other terms of the agreement were not disclosed.
The firm saw its Q4 revenues rise to $218,000 year over year, mainly due to expansion of its commercial liquid biopsy testing business.
Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
Upon entering the agreement, Aspire purchased $1 million in common stock, and may purchase up to $14 million more at Biocept's discretion.
The partners will use Biocept's liquid biopsy systems to detect estrogen receptor gene mutations that could help guide treatment for women with breast cancer.
Under the agreements, members of Fortified Provider Network and Three Rivers Provider Network will now have access to Biocept's liquid biopsy tests.
It accessioned 482 commercial cases during the quarter, nearly five times the 96 commercial cases for the third quarter of 2014.
Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.
The agreements with the PPOs bring the total number of Americans with covered access to Biocept's tests to about 31 million.
An increase in testing volume drove revenue growth in the quarter, though net loss also increased due to expenses associated with marketing and performing tests.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.